Horizon Headed For A Breakout Year As Tepezza Relaunch Exceeds Goals
Thyroid eye disease drug Tepezza is now expected to generate more than $1.55bn in full year sales, despite missing a full quarter of revenue.
Thyroid eye disease drug Tepezza is now expected to generate more than $1.55bn in full year sales, despite missing a full quarter of revenue.